Sharlene Gill, MD, MPH, FACP, FRCPC, highlights significant research data on developments in the treatment of GIST and NETs.
Yelena Janjigian, MD, Discusses HER2-Targeting Updates for Metastatic/Locally Advanced Esophageal, Gastric Cancers
Dr Janjigian shares her perspective on HER2-targeted therapy data from the DELIVER, KEYNOTE-061, DESTINY-Gastric01, and RTOG1010 trials.
Deborah Mukherji, MD, Talks Gaps in Research and Potential for Further Study on HCC, Biliary Tract Cancers
Dr Mukherji summarizes 3 posters that were presented at the 2020 ESMO World Congress on GI Cancer, which identify gaps in research and can inform future biliary tract cancer trials.
Anant Ramaswamy, MD, on the Efficacy of Capecitabine-Irinotecan vs Irinotecan for Advanced Gallbladder Cancer
Dr Ramaswamy provides perspective on a phase 2 trial comparing the efficacy of irinotecan administered with or without capecitabine for advanced gallbladder cancer.
Solange Peters, MD, PhD, discusses the motivation behind her Keynote Presentation on women in oncology, which will take place virtually on July 4th at the 2020 ESMO World Congress on GI Cancer.
Dr Grothey tells us what we can look forward to at the 22nd ESMO World Congress on Gastrointestinal Cancer, which is taking place virtually this year.
The President of ESMO discusses what attendees of the annual ESMO World Congress on GI Cancer can expect from the virtual 2020 event.
Metastatic GI Cancer: Dealing With the Complexity of Multiple Available Drugs Across Lines of Treatment
At ESMO World GI, experts reviewed optimal treatments and best sequencing based on level of evidence for various metastatic GI cancers.